Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02544061 · ClinicalTrials.gov registry record · Phase 2
NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds
A Phase 2 study, sponsored by Neumedicines.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02544061 is a Phase 2 study that has completed, run by Neumedicines. The registered enrollment target is 18 participants.
The verdict
NCT02544061, a Phase 2 study, has completed, sponsored by Neumedicines.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of NM-IL-12 relative to standard of care (SOC; control) in subjects with open surgical wounds.
Interventions
- DRUG Placebo
- BIOLOGICAL NM-IL-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2018-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02544061
The ClinicalTrials.gov registry entry for NCT02544061 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neumedicines, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02544061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02544061 about?
NCT02544061 is a clinical study titled "NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds". The purpose of this study is to determine the safety and tolerability of NM-IL-12 relative to standard of care (SOC; control) in subjects with open surgical wounds.
What is the current status of trial NCT02544061?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-03-01. Estimated completion is 2018-02-28.
What interventions are being tested in trial NCT02544061?
The interventions under investigation include: Placebo (DRUG), NM-IL-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02544061?
This trial is sponsored by Neumedicines, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.